Showing 1041-1050 of 5404 results for "".
- Rubedo Plans Clinical Trial of RLS-1496 for Androgenetic Alopeciahttps://practicaldermatology.com/news/rubedo-plans-clinical-trial-of-rls-1496-for-androgenetic-alopecia/2488446/Rubedo Life Sciences announced plans to evaluate its investigational GPX4 modulator RLS-1496 in patients with androgenetic alopecia (AGA), following ex vivo findings showing increased growth of human hair follicles exposed to the agent, according to an a
- FDA Approves Ameluz PDT for Superficial Basal Cell Carcinomahttps://practicaldermatology.com/news/fda-approves-ameluz-pdt-for-superficial-basal-cell-carcinoma/2488430/The US Food and Drug Administration (FDA) has approved Biofrontera Inc.’s supplemental New Drug Application for Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy (PDT) using the BF-RhodoLED lamp series for the treatment of superficial basal cell
- Cardamonin Shows Antifibrotic Activity in Human Keloid Fibroblasts: Studyhttps://practicaldermatology.com/news/cardamonin-shows-antifibrotic-activity-in-human-keloid-fibroblasts-study/2488327/Cardamonin demonstrated antifibrotic activity in human keloid fibroblasts by suppressing transforming growth factor β1 (TGF-β1)/Smad signaling, according to new in vitro research in the Journal of Drugs in Dermatology.
- Daily SPF Use Lags Among Youth: Surveyhttps://practicaldermatology.com/news/daily-spf-use-lags-among-youth-in-multigenerational-skincare-survey/2488298/Interest in facial skincare is growing among children and adolescents, new findings suggest. Researchers evaluated a 3-product regimen consisting of a hydrating cream cleanser, hydrating moisturizer, and daily mineral SPF 40
- PCA SKIN Launches Microbiome-Focused Acne Control Cleanserhttps://practicaldermatology.com/news/pca-skin-launches-microbiome-focused-acne-control-cleanser/2488268/PCA SKIN has launched Acne Control Prebiotic Gel Cleanser, a new daily cleanser formulated to address acne while supporting the skin barrier and microbiome, according to information provided by the company. The cleanser, laun
- Medical Creators Produce Higher-Quality Alopecia Areata Content on Social Media: Studyhttps://practicaldermatology.com/news/medical-creators-produce-higher-quality-alopecia-areata-content-on-social-media/2488252/A cross-sectional study of alopecia areata content on 3 major Chinese social media platforms found that video quality, reliability, and adherence to clinical guidance varied substantially by platform and creator background. Investigators evaluated 111 high-engagement educational videos ide
- Study Finds Racial Variation in Keloid Treatmenthttps://practicaldermatology.com/news/study-finds-racial-variation-in-keloid-treatment/2488178/An electronic health record analysis found differences in how keloids are treated across racial groups. In a Letter to the Editor published in the Journal of Drugs in Dermatology, investigators evaluated treatment patterns among adults with keloids using the TriNetX Research Netwo
- Monophasic HA Shows Longer-Term Benefit in Nasolabial Fold Correctionhttps://practicaldermatology.com/news/monophasic-ha-shows-longer-term-benefit-in-nasolabial-fold-correction/2488118/A randomized study comparing 2 types of hyaluronic acid (HA) dermal fillers found similar early improvements in moderate-to-severe nasolabial folds (NLFs), with outcomes favoring monophasic HA at 36 weeks. Galinde et al conducted a randomized, controlled, double-blinded, intraindividual st
- Upadacitinib Meets Primary Endpoint in Two Phase 3 Alopecia Areata Trialshttps://practicaldermatology.com/news/upadacitinib-meets-primary-endpoint-in-two-phase-3-alopecia-areata-trials/2488081/New data suggests upadacitinib was associated with significantly greater scalp hair regrowth than placebo among adults and adolescents with severe alopecia areata (AA), according to findings published online August 12 in JAMA Dermatology. The replicate UP-AA1 and UP-AA2 trials enr
- FDA Approves Tudriqev Plus Nivolumab for Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-tudriqev-plus-nivolumab-for-advanced-melanoma/2488043/The FDA has granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg; Replimune, Inc.) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on a programmed death receptor-1 (PD-1)–blocking antibody-based regimen, according